Seto WK - Search Results

1

Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.

Cheung KS, Ng HY, Hui RWH, Lam LK, Mak LY, Ho YC, Tan JT, Chan EW, Seto WK, Yuen MF, Leung WK. Cheung KS, et al. Among authors: seto wk. Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000855. Online ahead of print. Hepatology. 2024. PMID: 38536017

2

Mutational analysis for Wilson's disease.

Seto WK, Mak CM, But D, Hung I, Lam CW, Tam S, Yuen MF, Lai CL. Seto WK, et al. Lancet. 2009 Aug 22;374(9690):662. doi: 10.1016/S0140-6736(09)60915-6. Lancet. 2009. PMID: 19700008 Free article. No abstract available.

3

Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 Years.

Fung J, Lai CL, Yuen J, Cheng C, Wu R, Wong DK, Seto WK, Hung IF, Yuen MF. Fung J, et al. Among authors: seto wk. Hepatology. 2011 Apr;53(4):1148-53. doi: 10.1002/hep.24192. Hepatology. 2011. PMID: 21480321 Clinical Trial.

4

Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma.

Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF. Wong DK, et al. Among authors: seto wk. Hepatology. 2011 Sep 2;54(3):829-36. doi: 10.1002/hep.24551. Epub 2011 Jul 21. Hepatology. 2011. PMID: 21809355

5

Nucleic acid testing for the detection of HBV DNA.

Seto WK, Lai CL, Yuen MF. Seto WK, et al. Hepat Mon. 2011 Oct;11(10):847-8; author reply 849. doi: 10.5812/kowsar.1735143X.780. Hepat Mon. 2011. PMID: 22224085 Free PMC article. No abstract available.

6

A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance.

Seto WK, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, Tong T, Lai CL, Yuen MF. Seto WK, et al. Hepatology. 2012 Sep;56(3):812-9. doi: 10.1002/hep.25718. Epub 2012 Jul 10. Hepatology. 2012. PMID: 22422518

7

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.

Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Seto WK, et al. Hepatology. 2013 Sep;58(3):923-31. doi: 10.1002/hep.26376. Epub 2013 Jul 24. Hepatology. 2013. PMID: 23468172

8

Entecavir treatment in kidney transplant recipients infected with hepatitis B.

Yap DY, Yung S, Tang CS, Seto WK, Ma MK, Mok MM, Kwan LP, Chan GC, Choy BY, Yuen MF, Chan TM. Yap DY, et al. Among authors: seto wk. Clin Transplant. 2014 Sep;28(9):1010-5. doi: 10.1111/ctr.12410. Epub 2014 Jul 17. Clin Transplant. 2014. PMID: 24974788

9

Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis.

Yap DY, Seto WK, Fung J, Chok SH, Chan SC, Chan GC, Yuen MF, Chan TM. Yap DY, et al. Among authors: seto wk. Dig Liver Dis. 2017 Feb;49(2):202-206. doi: 10.1016/j.dld.2016.11.001. Epub 2016 Nov 10. Dig Liver Dis. 2017. PMID: 27876501

10

Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.

Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lau EHY, Cheung KS, Lie AKW, Lai CL, Kwong YL, Yuen MF. Seto WK, et al. Hepatology. 2017 May;65(5):1451-1461. doi: 10.1002/hep.29022. Epub 2017 Mar 22. Hepatology. 2017. PMID: 28027590

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

281 results

Search Page